Future therapies for obesity

Eka Melson; Alexander Dimitri Miras; Dimitris Papamargaritis

doi:10.7861/clinmed.2023-0144

Future therapies for obesity

Eka Melson
, Alexander Dimitri Miras
, Dimitris Papamargaritis

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

99 Downloads (Pure)

Abstract

Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management. [Abstract copyright: © Royal College of Physicians 2023. All rights reserved.]

Original language	English
Pages (from-to)	337-346
Number of pages	10
Journal	Clinical Medicine
Volume	23
Issue number	4
Early online date	31 Jul 2023
DOIs	https://doi.org/10.7861/clinmed.2023-0144
Publication status	Published online - 31 Jul 2023

Bibliographical note

Funding Information:
This work was supported by the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre.

Funding Information:
EM declares no conflict of interest. ADM has received grants or contracts from Fractyl, Novo Nordisk and Randox, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, AstraZeneca, Currax and Boehringer Ingelheim. DP has acted as a speaker for Novo Nordisk and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/ Diabetes UK and Health Education East Midlands.

Publisher Copyright:
© Royal College of Physicians 2023.

Funding

Funding Information: This work was supported by the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre. Funding Information: EM declares no conflict of interest. ADM has received grants or contracts from Fractyl, Novo Nordisk and Randox, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, AstraZeneca, Currax and Boehringer Ingelheim. DP has acted as a speaker for Novo Nordisk and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/ Diabetes UK and Health Education East Midlands. Publisher Copyright: © Royal College of Physicians 2023.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

obesity
gut hormones
tirzepatide
pharmacotherapy

Access to Document

10.7861/clinmed.2023-0144

Manuscript Clin Med 230331Author Accepted Manuscript, 153 KB

Cite this

@article{10a39302d3a24d14ba6fd3a177865ac9,

title = "Future therapies for obesity",

abstract = "Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management. [Abstract copyright: {\textcopyright} Royal College of Physicians 2023. All rights reserved.]",

keywords = "obesity, gut hormones, tirzepatide, pharmacotherapy",

author = "Eka Melson and Miras, \{Alexander Dimitri\} and Dimitris Papamargaritis",

note = "Funding Information: This work was supported by the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre. Funding Information: EM declares no conflict of interest. ADM has received grants or contracts from Fractyl, Novo Nordisk and Randox, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, AstraZeneca, Currax and Boehringer Ingelheim. DP has acted as a speaker for Novo Nordisk and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/ Diabetes UK and Health Education East Midlands. Publisher Copyright: {\textcopyright} Royal College of Physicians 2023.",

year = "2023",

month = jul,

day = "31",

doi = "10.7861/clinmed.2023-0144",

language = "English",

volume = "23",

pages = "337--346",

journal = "Clinical Medicine",

issn = "1470-2118",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Future therapies for obesity

AU - Melson, Eka

AU - Miras, Alexander Dimitri

AU - Papamargaritis, Dimitris

N1 - Funding Information: This work was supported by the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre. Funding Information: EM declares no conflict of interest. ADM has received grants or contracts from Fractyl, Novo Nordisk and Randox, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, AstraZeneca, Currax and Boehringer Ingelheim. DP has acted as a speaker for Novo Nordisk and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/ Diabetes UK and Health Education East Midlands. Publisher Copyright: © Royal College of Physicians 2023.

PY - 2023/7/31

Y1 - 2023/7/31

N2 - Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management. [Abstract copyright: © Royal College of Physicians 2023. All rights reserved.]

AB - Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management. [Abstract copyright: © Royal College of Physicians 2023. All rights reserved.]

KW - obesity

KW - gut hormones

KW - tirzepatide

KW - pharmacotherapy

UR - https://www.scopus.com/pages/publications/85168130908

U2 - 10.7861/clinmed.2023-0144

DO - 10.7861/clinmed.2023-0144

M3 - Article

C2 - 37524416

SN - 1470-2118

VL - 23

SP - 337

EP - 346

JO - Clinical Medicine

JF - Clinical Medicine

IS - 4

ER -

Future therapies for obesity

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this